基因型指导华法林剂量对髋或膝关节置换术患者临床事件和抗凝控制的影响:GIFT随机临床试验
GIFT随机临床试验纳入1650例65岁及以上因择期髋或膝关节置换术开始华法林治疗的患者,在6个美国医学中心开展。基因型指导组(n=831)与临床指导组(n=819)相比,主要终点复合事件(大出血、INR≥4、静脉血栓栓塞或死亡)发生率分别为10.8% vs 14.7%(绝对差异3.9%,95%CI 0.7%-7.2%,P=.02;RR 0.73,95%CI 0.56-0.95)。作者认为基因型指导 dosing 降低了复合风险,需进一步研究个性化华法林 dosing 的成本效益。
要点
- 基因型指导华法林剂量组主要终点事件10.8%,临床指导组14.7%,绝对差异3.9%(95%CI 0.7%-7.2%,P=.02)。
- INR≥4事件基因型指导组56例 vs 临床指导组77例(RR 0.71,95%CI 0.51-0.99)。
- 大出血事件基因型指导组2例 vs 临床指导组8例(RR 0.24,95%CI 0.05-1.15),两组均无死亡。
核心结论
- 在择期髋或膝关节置换术并接受围手术期华法林治疗的患者中,与临床指导剂量相比,基因型指导华法林剂量降低了主要出血、INR≥4、静脉血栓栓塞或死亡的复合风险。
- 需要进一步研究以确定个性化华法林剂量的成本效益。
研究设计与样本
- GIFT随机临床试验在美国6个医学中心开展,纳入65岁及以上因择期髋或膝关节置换术开始华法林治疗的患者。
- 采用2×2析因设计,患者随机接受基因型指导(n=831)或临床指导(n=819)华法林剂量(治疗第1至11天),并随机分配至INR目标1.8或2.5。
- 纳入分析1650例随机患者(平均年龄72.1岁,SD 5.4岁;女性63.6%;白人91.0%),其中1597例(96.8%)至少接受1剂华法林并完成试验(基因型指导组n=808 vs 临床指导组n=789)。
主要发现
- 基因型指导组87例(10.8%)vs 临床指导组116例(14.7%)发生至少1个主要终点事件(绝对差异3.9%,95%CI 0.7%-7.2%,P=.02;RR 0.73,95%CI 0.56-0.95)。
- 大出血事件基因型指导组2例 vs 临床指导组8例(RR 0.24,95%CI 0.05-1.15)。
- INR≥4事件基因型指导组56例 vs 临床指导组77例(RR 0.71,95%CI 0.51-0.99)。
- 静脉血栓栓塞事件基因型指导组33例 vs 临床指导组38例(RR 0.85,95%CI 0.54-1.34)。
- 两组均无死亡。
关键数值与推荐
- 主要终点为复合终点:大出血、INR≥4、静脉血栓栓塞或死亡。
- 基因型检测多态性:VKORC1-1639G>A、CYP2C9*2、CYP2C9*3、CYP4F2 V433M。
- 华法林治疗第1至11天进行剂量调整,INR目标为1.8或2.5。
- 术后约1个月进行下肢双功能超声筛查。
临床怎么用
- 作者结论认为,在择期髋或膝关节置换术并接受围手术期华法林治疗的患者中,与临床指导剂量相比,基因型指导华法林剂量降低了主要出血、INR≥4、静脉血栓栓塞或死亡的复合风险。
- 作者指出需要进一步研究以确定个性化华法林剂量的成本效益。
局限性
- 需要进一步研究以确定个性化华法林剂量的成本效益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Warfarin use accounts for more medication-related emergency department visits among older patients than any other drug. Whether genotype-guided warfarin dosing can prevent these adverse events is unknown. OBJECTIVE: To determine whether genotype-guided dosing improves the safety of warfarin initiation. DESIGN, SETTING, AND PATIENTS: The randomized clinical Genetic Informatics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis included patients aged 65 years or older initiating warfarin for elective hip or knee arthroplasty and was conducted at 6 US medical centers. Enrollment began in April 2011 and follow-up concluded in October 2016. INTERVENTIONS: Patients were genotyped for the following polymorphisms: VKORC1-1639G>A, CYP2C9*2, CYP2C9*3, and CYP4F2 V433M. In a 2 × 2 factorial design, patients were randomized to genotype-guided (n = 831) or clinically guided (n = 819) warfarin dosing on days 1 through 11 of therapy and to a target international normalized ratio (INR) of either 1.8 or 2.5. The recommended doses of warfarin were open label, but the patients and clinicians were blinded to study group assignment. MAIN OUTCOMES AND MEASURES: The primary end point was the composite of major bleeding, INR of 4 or greater, venous thromboembolism, or death. Patients underwent a screening lower-extremity duplex ultrasound approximately 1 month after arthroplasty. RESULTS: Among 1650 randomized patients (mean age, 72.1 years [SD, 5.4 years]; 63.6% women; 91.0% white), 1597 (96.8%) received at least 1 dose of warfarin therapy and completed the trial (n = 808 in genotype-guided group vs n = 789 in clinically guided group). A total of 87 patients (10.8%) in the genotype-guided group vs 116 patients (14.7%) in the clinically guided warfarin dosing group met at least 1 of the end points (absolute difference, 3.9% [95% CI, 0.7%-7.2%], P = .02; relative rate [RR], 0.73 [95% CI, 0.56-0.95]). The numbers of individual events in the genotype-guided group vs the clinically guided group were 2 vs 8 for major bleeding (RR, 0.24; 95% CI, 0.05-1.15), 56 vs 77 for INR of 4 or greater (RR, 0.71; 95% CI, 0.51-0.99), 33 vs 38 for venous thromboembolism (RR, 0.85; 95% CI, 0.54-1.34), and there were no deaths. CONCLUSIONS AND RELEVANCE: Among patients undergoing elective hip or knee arthroplasty and treated with perioperative warfarin, genotype-guided warfarin dosing, compared with clinically guided dosing, reduced the combined risk of major bleeding, INR of 4 or greater, venous thromboembolism, or death. Further research is needed to determine the cost-effectiveness of personalized warfarin dosing. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01006733.
引用
- Gage BF, Bass AR, Lin H, et al. Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial. JAMA. 2017. PMID: 28973620. doi:10.1001/jama.2017.11469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。